Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.68 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111458 | 0.87 | MAP2K1 (0.76) | MAP2K1MAP2K2 | |
| SCHEMBL1111486 | 0.81 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL12831816 | 0.81 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL17121641 | 0.81 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL2725624 | 0.79 | MAP2K1 (0.77) | MAP2K1 | |
| SCHEMBL14022035 | 0.73 | MAP2K1 (0.83) | MAP2K1 | |
| SCHEMBL4545277 | 0.73 | MAP2K1 (0.68) | MAP2K1 | |
| SCHEMBL3663047 | 0.70 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL389985 | 0.70 | MAP2K1 (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL2953672 | 0.70 | MAP2K1 (0.67) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | claimed |
| EP-2279166-A1 | SUBSTITUTED PHENOXYBENZAMIDES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | claimed |
| WO-2009129938-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | claimed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | CCNB3, VEGFA, CCND2 | MAP2K1 3245/4885MAP2K2 2666/4885BRAF 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.